{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-102878","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.698494+00:00","generated_at":"2026-05-31T06:37:27.594989+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Director John Jenkins adopts 10b5-1 plan to sell up to 5,436 CRBP shares","bullets":["Plan covers up to 5,436 shares of common stock, effective November 30, 2024.","Plan terminates on November 29, 2025, per Rule 10b5-1(c) affirmative defense.","Dr. Jenkins is a member of the board of directors of Corbus Pharmaceuticals.","Trading plan adopted on August 29, 2024; sales may begin after the 90-day cooling-off period."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-102878","json":"https://secwatch.observer/filing/0000950170-24-102878.json","markdown":"https://secwatch.observer/filing/0000950170-24-102878.md","text":"https://secwatch.observer/filing/0000950170-24-102878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024102878/0000950170-24-102878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024102878/crbp-20240829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:37:27.594989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}